Active substance
Results for the substance daunorubicin+cytarabine
1 result
About this active substance
The combination of Daunorubicin + cytarabine is used for the treatment of acute myeloid leukemia (AML), particularly in newly diagnosed patients. It combines the chemotherapeutic effects of daunorubicin and cytarabine to destroy cancer cells and induce remission.
The medications are administered intravenously according to a specific regimen and are effective in reducing tumor burden and prolonging patient survival. This combination is considered standard in AML treatment.
Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and an increased risk of infections. In rare cases, cardiac toxicity or other severe complications may occur. Close monitoring is essential.
Consult your doctor to discuss the benefits and risks of treatment with Daunorubicin + cytarabine. Follow all medical recommendations to ensure treatment effectiveness.
The medications are administered intravenously according to a specific regimen and are effective in reducing tumor burden and prolonging patient survival. This combination is considered standard in AML treatment.
Side effects may include nausea, vomiting, hair loss, bone marrow suppression, and an increased risk of infections. In rare cases, cardiac toxicity or other severe complications may occur. Close monitoring is essential.
Consult your doctor to discuss the benefits and risks of treatment with Daunorubicin + cytarabine. Follow all medical recommendations to ensure treatment effectiveness.